CE Marking Cost and Timeline for Medical Software

The honest answer to "how much does CE marking cost" is a range, and the range is wide enough that quoting a single number would mislead more founders than it helped. This guide breaks down what actually drives the cost and the time, so you can budget against your specific situation rather than a headline figure. The work being costed is set out step by step in CE marking for medical device software.

In short: For Class IIa–III software, CE marking is commonly cited at roughly 12–18 months with an initial investment of EUR 120,000–300,000, an industry-cited range including regulatory consultancies and market analysts such as posos.co, not a Venitara quote. The largest cost drivers are the QMS build, clinical evaluation, and Notified Body fees; the largest delays come from documentation gaps and NB backlog.

The honest range, and why it's a range

Industry sources, including regulatory consultancies and market analysts such as posos.co, commonly cite Class IIa to III software CE marking at 12 to 18 months and an initial investment in the EUR 120,000 to 300,000 range. These figures are widely repeated because they are directionally useful, not because they are precise for any specific product. The range is wide because the two biggest variables, how mature your quality management system and technical documentation already are when you start, and which Notified Body you engage and their current capacity, vary enormously between teams and are largely outside the figures themselves.

A team that starts with a genuinely blank page, no QMS, no documented risk management process, no clinical evaluation started, sits at the top of both ranges. A team that has already run a disciplined design and development process, with contemporaneous documentation, can sit meaningfully below the midpoint on both cost and time, not because they found a shortcut, but because they are not paying to reconstruct evidence that should have existed from the start.

It helps to think about the range as answering two separate questions rather than one. The cost figure answers "how much evidence and process do we need to build." The timeline figure answers "how long does it take a Notified Body to check that work, on top of however long the building itself takes." A team can compress the first number substantially through early discipline. The second number is harder to compress, because it depends partly on a Notified Body's own queue, which is outside any single applicant's control.

One forward-looking note, clearly not yet law: in December 2025 the European Commission published a proposal to simplify the MDR and IVDR (COM(2025) 1023, procedure 2025/0404(COD)) which would, among other things, move much stand-alone software toward Class I self-declaration — a change that would materially lower the cost basis for some software by removing Notified Body review from the path entirely. It is a proposal, not law, and adoption is realistically ~2027 at the earliest, so budget against the current rules while factoring the possible change into longer-term strategy.

Cost breakdown by artefact

Quality management system. Building or upgrading an ISO 13485-aligned QMS is usually the single largest line item for a team starting from nothing, covering process documentation, internal audits, document control infrastructure, and the organisational discipline to run it. Teams that build this early and keep it live through development, rather than retrofitting it before submission, consistently spend less here.

Technical documentation and risk management. The Annex II/III technical file and the ISO 14971 risk management file are labour-intensive to build well, particularly the traceability between requirements, risks, verification, and validation that a Notified Body will scrutinise closely. Building an MDR Technical File and CER breaks this artefact down in detail.

Clinical evaluation. Cost here depends heavily on route: a literature-based equivalence argument is materially cheaper than a dedicated clinical investigation, but equivalence arguments are becoming harder to sustain under MDR's stricter evidentiary bar than under the previous directive, particularly for higher-class devices.

Notified Body fees. These are set by the Notified Body itself and vary by device class, complexity, and the specific body engaged; they are a real and significant cost but typically a smaller share of total spend than the QMS and technical documentation build.

PRRC and ongoing compliance infrastructure. The Person Responsible for Regulatory Compliance role, required under MDR Article 15, and the surrounding compliance infrastructure are smaller line items individually but add up as ongoing costs that persist after certification, not one-time submission costs. PRRC Under MDR Article 15: What to Know covers what small teams underestimate here.

A worked example. Take a Class IIa clinical decision-support product built by a five-person team with no prior regulatory experience. Building the QMS from scratch, including process documentation, document control, and getting internal audits running, is realistically the largest single line item, often landing in the EUR 40,000-70,000 range once consulting support and staff time are both counted — to be clear, that narrower figure is Venitara's own illustrative sub-allocation of the industry-cited EUR 120,000-300,000 headline range above, not an independently sourced statistic, so treat it as an illustration of how the headline range distributes rather than a number to budget against directly. The technical file and ISO 14971 risk management file, built properly with real requirements-to-risk-to-verification traceability rather than assembled retroactively, is usually the second-largest cost, particularly if verification and validation testing needs to be redone because the original testing wasn't documented to a standard a Notified Body will accept. Clinical evaluation for a product like this, if it can lean on a literature-based equivalence argument rather than a dedicated clinical investigation, tends to be a smaller though still meaningful cost. Notified Body fees themselves, for a Class IIa software product, are typically a smaller share of the total than founders expect going in, more comparable to the PRRC and compliance-infrastructure line than to the QMS or technical file build. Add these up for a team starting from nothing and the EUR 120,000-300,000 range stops looking abstract; it's a reasonably direct sum of five or six line items, most of which are labor and documentation discipline rather than fees paid to a third party.

Timeline by phase, and where the NB backlog bites

The 12 to 18 month range typically breaks into three rough phases: internal preparation (QMS build, technical file assembly, risk management, clinical evaluation), which is the phase most within your control and most compressible with early, disciplined work; Notified Body review, which includes their initial documentation review, any rounds of questions and clarifications, and final decision, and which is the phase least within your control; and post-certification setup (declaration of conformity, CE marking, launch readiness), typically the shortest phase.

Notified Body capacity has been a persistent bottleneck since MDR's introduction, as the number of designated bodies did not scale with demand at the same pace as the regulation's stricter requirements increased the volume and depth of review needed per submission. This means the Notified Body review phase is often the single largest source of schedule variance between an optimistic plan and actual experience, and it is worth building schedule margin around this phase specifically rather than assuming your internal preparation timeline is the only variable that matters.

What makes projects cheaper and faster, and what falsely promises to

Teams that consistently land toward the lower end of both ranges share a few habits: they build their QMS and start documentation contemporaneously with product development, not as a pre-submission scramble; they engage regulatory expertise early enough to catch classification and evidence-strategy mistakes before they are baked into the product, rather than after; and they choose a Notified Body appropriately matched to their device type and complexity rather than defaulting to the first available slot — bearing in mind that not every Notified Body is designated for every MDR device code, so the availability of a body covering your specific code can itself gate the timeline and your negotiating position.

What does not reliably make projects cheaper or faster, despite frequently being marketed as though it does, is worth naming plainly, because both patterns below cost teams real money when they're taken at face value. Software tools that generate technical documentation templates promise to compress the QMS and technical file build into a fill-in-the-blanks exercise. What they can't do is supply the regulatory judgment a Notified Body is actually reviewing: whether your risk controls are the right ones for your specific device, whether your verification evidence actually traces to your requirements, whether your clinical evaluation's equivalence argument holds up. A Notified Body reviews substance, not template completeness, and a beautifully formatted file built on thin underlying analysis fails review just as often as a messy one, sometimes more often, because the polish creates an expectation of rigor the content doesn't back up.

Consultancies or platforms that imply, directly or through phrasing like "accelerated review" or "priority NB access," that they can expedite Notified Body review timelines are making a claim that doesn't match how NB capacity actually works. Notified Bodies are independent, accredited organizations; queue position and review depth are set by their own capacity and internal process, not by fees paid to a third party who claims a relationship with them. What such a service can sometimes do is help you avoid the documentation gaps that generate additional review rounds, which does shorten your effective timeline. That's a real and legitimate value, but it's a different claim than "we can make the Notified Body go faster," and the distinction matters when you're evaluating who to pay for help.

Where teams underestimate the internal preparation phase specifically

The internal preparation phase is the one most within a team's control, which makes it the phase where optimistic planning does the most damage. Founders building their first regulatory timeline often model this phase against how long the work would take a specialist team working full time, without accounting for the fact that a five-person startup is doing this alongside product development, fundraising, and everything else a growing company runs on simultaneously. A realistic internal preparation timeline for a team with no regulatory head start looks less like a dedicated sprint and more like a sustained, months-long parallel workstream, with real risk of drift if nobody owns it as their primary responsibility. Teams that assign clear ownership of the technical file and QMS build to a specific person, even part time, consistently move faster through this phase than teams treating it as a shared responsibility that everyone is nominally accountable for.

Budgeting rules of thumb for a seed-stage team

Treat the lower end of the cited ranges as achievable only if your documentation discipline starts now, not at submission time. Budget contingency specifically around Notified Body review timing, since this is the phase most likely to run longer than planned regardless of how well-prepared your internal file is. And separate your one-time certification costs from your ongoing post-market costs, PRRC, post-market surveillance, periodic safety update reports for higher classes, vigilance system maintenance, and EUDAMED registration, since these persist for the life of the product and are frequently under-budgeted by teams focused entirely on reaching first certification. EUDAMED deserves explicit mention because it is often missing from budget lists: the first modules, including actor registration and UDI/device registration, have been mandatory since 28 May 2026 under Regulation (EU) 2024/1860, and registration carries real setup effort — actor registration, UDI assignment, device registration — that belongs in the plan as its own line item, not an assumed by-product of certification.

What a first-pass failure costs you

A Notified Body rejecting or returning a submission with significant findings does not just cost the time to address those findings; it costs a second full review cycle, which in a capacity-constrained system can mean a materially longer total timeline than if the submission had been complete the first time. This is the strongest practical argument for investing in getting the technical file right before submission rather than treating the Notified Body's review as a first draft of your quality checking. A submission returned for significant findings isn't unusual, and it doesn't mean the underlying product is flawed; it usually means the evidence behind a specific claim wasn't documented to the depth or traceability the Notified Body needed to see. Why Most 510(k)s Get an Information Request makes a parallel argument for the US route: the underlying lesson, that documentation completeness at first submission is the highest-leverage timeline lever available to a founder, holds across both systems.

Frequently asked questions

Can CE marking genuinely be done for less than EUR 120,000? For a very simple, low-complexity Class IIa product with an unusually mature starting QMS, costs below the commonly cited range are possible, but this is the exception rather than something to plan a budget around. Most teams building genuine clinical decision-support software should plan within or above the cited range.

Does the cost range include ongoing post-market costs? No, the cited range covers the initial path to certification. Ongoing costs, PRRC, post-market surveillance, periodic reporting for higher classes, vigilance system maintenance, and EUDAMED registration and data maintenance (mandatory since 28 May 2026), are separate and continue for the life of the product on the market.

Can we speed up Notified Body review by paying more? No party can reliably purchase faster Notified Body review; queue position and review depth are set by the Notified Body's own capacity and process, not by fees paid. What genuinely shortens review time is submission completeness, since incomplete or poorly organised files generate more rounds of questions.

Is the timeline different for a device that's already CE marked and being updated? Yes, often significantly shorter, since a change to an already-certified device typically requires a change assessment against the existing certificate rather than a full initial conformity assessment, though a change substantial enough to affect classification or intended purpose can trigger a fuller review.

How do EU costs compare to a US 510(k)? Both involve broadly comparable investment for equivalent-complexity software, with the 510(k) commonly cited at USD 150,000–350,000 including consulting against a 6–12 month timeline, an industry-cited range including regulatory consultancies and market analysts such as posos.co, versus the EU's EUR 120,000–300,000 against 12–18 months. CE Mark vs FDA Clearance: The Real Differences covers what evidence transfers between them.

Can we switch Notified Bodies partway through if ours is too slow? Technically yes, but it rarely saves time in practice. A new Notified Body starts its review largely from scratch, since it has no institutional familiarity with your file, and the switching process itself, including transferring documentation and establishing a new contractual relationship, takes real time. It's occasionally the right call if a specific Notified Body relationship has broken down entirely, but "our NB is slower than we hoped" is usually better addressed by improving submission completeness than by switching bodies mid-review.

Do these figures assume a EU-based team, or does it cost more for a non-EU company? The cited range is broadly applicable regardless of where the manufacturer is based, but a non-EU manufacturer has one additional mandatory cost the range doesn't separately call out: an EU Authorised Representative, a formal local presence required for any manufacturer without an established place of business in the EU. This is usually a smaller ongoing cost relative to the QMS and technical file build, but it's a real one that a non-EU team should budget for explicitly rather than assume is folded into the headline range.

How should a seed-stage team with limited runway sequence this spend? Front-load the cheapest, highest-leverage work first: getting your classification confirmed, since it determines which of the ranges above actually applies to you, and starting contemporaneous documentation of design and development work you're doing anyway. Both cost relatively little in isolation and meaningfully reduce the risk of expensive rework later. Defer the largest single-cash-outlay items, dedicated clinical evaluation work and Notified Body engagement itself, until the underlying technical file is far enough along that the NB's review has a real chance of going smoothly the first time, since a rejected or heavily-queried first submission is the single most expensive mistake available in this process.

The free MedTech Compass can help you understand which class and evidence requirements likely apply to your specific product, which is the starting point for building a realistic budget rather than working from headline industry figures alone.

---

Where next: MDR Annex VIII: How Device Classes Are Set · PRRC Under MDR Article 15: What to Know · Why Most 510(k)s Get an Information Request · Where to Launch First: EU, UK, or US?

Find out what class and evidence requirements likely apply to your product. Start the MedTech Compass →